Basic Information
| LncRNA/CircRNA Name | FAM215A |
| Synonyms | NA |
| Region | GRCh38_17:43917194-43917985 |
| Ensemble | ENSG00000267496 |
| Refseq | NR_026770 |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | doxorubicin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | liver cancer |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, RIP etc. |
| Sample | HCC tissues and corresponding adjacent normal tissues, cell lines (Hep3B, Mahlavu, and J7) |
| Expression Pattern | up-regulated |
| Function Description | Together, our results show that the lncRNA, FAM215A, is highly expressed in HCC, where it interacts with and stabilizes LAMP2 to increase tumor progression while decreasing doxorubicin sensitivity. |
| Pubmed ID | 32295144 |
| Year | 2020 |
| Title | Dysregulated FAM215A Stimulates LAMP2 Expression to Confer Drug-Resistant and Malignant in Human Liver Cancer. |
External Links
| Links for FAM215A | GenBank HGNC Noncode |
| Links for liver cancer | Omim Cosmic |